Medicenna Therapeutics Corp. (MDNA) SEC Filing 6-K Foreign Issuer Report for the period ending Thursday, February 10, 2022

Medicenna Therapeutics Corp.

CIK: 1807983 Ticker: MDNA

View differences made from one to another to evaluate Medicenna Therapeutics Corp.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Medicenna Therapeutics Corp..


Assess how Medicenna Therapeutics Corp.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Medicenna Therapeutics Corp.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Medicenna Therapeutics Corp. provided additional information to their SEC Filing as exhibits

Ticker: MDNA
CIK: 1807983
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001171843-22-000923
Submitted to the SEC: Thu Feb 10 2022 7:05:09 AM EST
Accepted by the SEC: Thu Feb 10 2022
Period: Thursday, February 10, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: